Latest updates
- In the press OBN Awards 2025
- In the press Exonate plans ‘CLEAR-DE’ Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease
- In the press Exonate appoints Dr Rafiq Hasan as Non-Executive Director
- In the press Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation
- In the press Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
- Insights Biotech Showcase, San Francisco 2024
- Insights Exonate at Biotrinity 2022
- Company news Exonate at Biotrinity 2021
- Insights Exonate announces involvement in exciting STEM outreach project.
- In the press Exonate announces the initiation of Phase Ib/II clinical trial for Diabetic Macular Oedema, as part of its collaboration with Janssen
- Company news Exonate receives regulatory approval to start Phase I Clinical Trials in Australia
- Company news Exonate completes Wellcome Trust Seeding Drug Discovery Award programme